Short-course 3HP TB prevention options for people living with HIV
Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options Trial
This project compares a simpler support package versus routine care to help people living with HIV finish a 12-week, once-weekly TB preventive medicine called 3HP.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11378910 on NIH RePORTER |
What this research studies
If you join, you'll be enrolled at an HIV clinic and randomly placed into either routine self‑care or a simplified support approach that adds brief counseling, automated phone reminders and check-ins, and phone-based pill reporting (99DOTS). The medication is 3HP, taken once weekly for 12 weeks, and staff will track whether people finish the full course and any side effects. The team built on a prior Uganda trial that showed high completion with similar support and is testing whether simplified support works across many clinics. They will also look at how easy the approach is to use in real clinics and whether it saves time or money.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV who are eligible for TB preventive therapy and willing to take the 12-week once-weekly 3HP regimen at a participating clinic.
Not a fit: People who already completed TB preventive therapy, who have active TB disease, or who cannot take isoniazid or rifapentine due to allergy or drug interactions are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could help more people living with HIV complete short-course TB prevention and reduce their risk of developing active tuberculosis.
How similar studies have performed: A prior single-center randomized trial in Uganda showed very high completion (about 92%) with facilitated self-administered 3HP, but this simplified package still needs testing across many clinics.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Cattamanchi, Adithya — University of California-Irvine
- Study coordinator: Cattamanchi, Adithya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.